How to Scale Organoid Screening with Bundled Platforms
- Advanced Solutions
- 8 minutes ago
- 2 min read
The Challenge: Scaling Organoid Screening Beyond the Manual Bottleneck
As NAMs models such as organoids gain traction across disease modeling, drug discovery, and personalized medicine, one major challenge persists - scaling organoid screening efficiently and reproducibly.
Manual workflows introduce variability, low throughput, and long timelines, especially when dealing with a wide variety of samples. For many labs, the question isn’t how to generate organoids - it’s how to scale their generation, handling, and analysis without compromising biological integrity.
Roadblocks of Manual Organoid Workflows
Traditional organoid screening involves multiple manual steps:
Seeding cells into matrices
Culturing and feeding
Imaging and endpoint assays
Each of these steps introduces potential for variability - both between users and across plates. This becomes particularly limiting when scaling to 96-, or 384-well formats.
Organoid screening demands precision, consistency, and gentle handling, which are difficult to achieve manually.
Finding new routes with Bundled Platforms
Advanced Solutions Life Sciences (ASLS) eliminates these scaling roadblocks with an integrated, bundled platform approach that unifies hardware, software, and data workflows.
By combining pre-loaded BioApps™ and a pre-configured BioAssemblyBot®, researchers gain a connected ecosystem designed for throughput, reproducibility, and automation - all while maintaining cell viability.
Automates organoid formation, culture, and analysis through modular, closed-loop control. The system supports repeatable organoid assays with high levels of accuracy and precision.
"ASLS has been a great partner and BAB has helped us deliver consistent, robust data from our stem cell biology and 3D biofabrication programs for developing bioengineered kidneys. The speed and reproducibility has been integral to our evaluation of therapeutic tissue strategies.”
- Ben Shepherd, Trestle Bio Co-Founder and CEO.
The Future of Scalable Organoid Screening
The path to scalable organoid screening isn’t just about automation - it’s about integrated intelligence. With BAB Intelligence™, ASLS is taking the next step toward adaptive, AI-driven biofabrication workflows that can learn, predict, and optimize in real time.
By adopting a bundled, connected approach today, your lab can future-proof its organoid research for tomorrow’s discoveries.
Ready to Scale?
Discover how Advanced Solutions Life Sciences can help you design and deploy scalable organoid workflows.